November 22nd, 2020 by Johnna Crider
Tesla has partnered with Curevac to help fight the coronavirus, but what is the extent of this partnership? Ive seen claims all over Twitter from a few of Elon Musks critics saying that he should stick to making rockets. Honestly, telling someone with Elons net worth to not help is kind of rude, if you ask me. Opinions and thoughts about that matter aside, NZZ gives a detailed breakdown of Teslas partnership with Curevac, and no, Elon is not in some lab with a syringe filled with God only knows what while standing over a poor hapless soul strapped down to a gurney (visions that may come to mind if you look at some of the tweets out there).
This partnership is actually older than the coronavirus itself, and shows that many armchair critics and click chasers havent really done their research. The first takeaway from the German article is that Curevac and Tesla are working together on an RNA printer. Tesla is helping by building the parts of an RNA printer that will produce not only this vaccine, but also others and other medicines. That said, we should all recognize that this is no normal printer. Anyone who imagines an RNA printer as a handy printer that will shortly spit out vaccines against Sars-CoV-2, for example, is not entirely correct, the author of the article noted before explaining the story of this partnership.
Curevac, founded in 2000, was the first biotech company to work with the messenger molecule mRNA (messenger ribonucleic acid) for the fields of oncology, protein therapy, and vaccines. It came to the conclusion years ago that it needed an industrial plan in order to conduct clinical studies at all and then produce billions of doses annually, according to its CEO, Franz-Werner Haas. After that, the company wanted to eventually produce smaller quantities at a faster pace something geared toward personalized medicine. For example, its a matter of producing a personalized active ingredient for an oncology patient. This would take too much time on a large system, and the quantities would also be too large. Curevac needed additional support to implement its idea of mobile production units, stating, We are biologists, we are doctors, we are technicians, but we are not mechanical engineers. With this in mind, the company brought in Grohmann Engineering as a technical partner, which Tesla bought and is now Tesla Grohmann Automation.
An RNA printer, the article points out, is a small mobile production facility (not a printer you plug in, press a button, and print from) that is made for a certain type of pharmaceutical. It uses a specific RNA sequence as an active ingredient. This field of application is not limited to vaccines it is also being tested for antibody therapies for various diseases. These diseases range from personalized cancer medicine to gene therapy using the Crispr/Cas technique.
A Curevac spokesman described the RNA printer, which is still a prototype, as a mini-factory that is 34 meters long, 2 meters wide, and 2 meters high. Its slightly larger than an SUV and can be shipped in a container. Additionally, work is being done to make it smaller and give it more functions.
The article noted that the focus for right now will most likely be on vaccines, and that extensive immunization against certain pathogens is pretty much a logistical problem. When a vaccine is distributed, it requires a functioning cold chain from the manufacturer to the most remote village. Also, RNA is often an unstable molecule that decomposes quickly even at room temperature. Often when transporting it, the temperature has to be at least -20 to sometimes -80 degrees Celsius.
Curevac is actually working on an idea of making any mRNA vaccine directly where it is needed. This, the author pointed out, is what the RNA printer could do. The printer consists of a bioreactor in which the DNA template is overwritten in RNA. Next, the finished messenger molecules are freed from the process chemicals and then embedded in fat droplets, which prevent them from decomposing too quickly.
Grohmann Engineering GmbH, which is an engineering automation company, was acquired by Tesla in 2016. It was officially taken over by Tesla on January 3, 2017. Back then, the partnership was uncertain, and Curevac actually sent representatives to California to encourage Tesla to continue the collaboration. Tesla, as we all see clearly, did so, in addition to Tesla Grohmanns is focused on automation processes for the production of EVs and power storage systems.
With this bit of history in mind, its easy to see how it was natural for Elon Musk and Tesla to get involved with creating a vaccine for the coronavirus. Many dont take the time to fully research this partnership and are quick to loathe Elon Musk for being Elon Musk someone who wants to help. Whether calling it a publicity stunt, stock manipulation, or whatever the critics say these days, its clear that those who seek to criticize are not doing their research.
If one was doing actual research, they would have not only realized that Tesla is working with Curevac to make molecule printers, but that the company has been working with Curevac behind the scenes since Tesla acquired Grohmann Engineering GmbH 4 years ago. And the research would have you understand that Teslas engineers are working in partnership with Curevac in a meaningful way. Just note that they are making the mechanical parts of the printer, not the actual vaccine itself.
Speaking of the vaccine, in a video call with members of the press, Haas explained that Curevac had good feedback on its Phase 1 trials and is moving into Phases 2 and 3. Curevac is also recruiting 36,000 participants. A virus doesnt differentiate between nationality, sex, skin color, religion it is an international problem, that must be tackled internationally. He added that, I will say it in the words of Bill Gates he said it four years ago such outbreaks will happen again and again. The thing is we dont know what they will be and when they will come.
I think I learned more about RNA and mRNA writing this article than I did in school. And what Ive gathered from this is that the folks at Curevac the actual scientists making the vaccine know what they are doing and know what they need from Tesla. Tesla is helping and meeting that need, and has years of experience working with Curevac.
Tesla helping the vaccine would be the equivalent of me giving some copper wire to a friend who works in electrical engineering. I know nothing about the engineering work they do, but I use copper in my art and can get them some.
We dont know the type of benefit Tesla is receiving from Curevac, but we do know that Teslas contribution is something that will help save lives and create a valuable asset to the medical field. Actually, Elon Musk has stated before that Tesla isnt going to financially benefit from this. Emotionally, Teslas staff may benefit, especially if Curevacs prototype that Tesla is helping to create becomes a world-changing success in the medical industry what they are hoping it to be. And this, in my opinion, is why I believe Elon and Tesla are working with Curevac to help.
Im interested in things that change the world or that affect the future and wondrous, new technology where you see it, and youre like, Wow, how did that even happen? How is that possible? Elon Musk
Appreciate CleanTechnicas originality? Consider becoming aCleanTechnica member, supporter, or ambassador or apatron on Patreon.
Sign up for our free daily newsletter or weekly newsletter to never miss a story.
Have a tip for CleanTechnica, want to advertise, or want to suggest a guest for our CleanTech Talk podcast? Contact us here.
Tags: CureVac, Grohmann Engineering, Tesla, Tesla Grohmann, Tesla Grohmann Automation
Johnna Crider is a Baton Rouge artist, gem, and mineral collector, member of the International Gem Society, and a Tesla shareholder who believes in Elon Musk and Tesla. Elon Musk advised her in 2018 to Believe in Good.Tesla is one of many good things to believe in. You can find Johnna on Twitter
See the original post:
History of the Partnership between Tesla & Curevac Its Older than Covid-19 - CleanTechnica
- Personalized medicine: The pros, cons and concerns - New Atlas - November 16th, 2024
- Precision Medicine, AI, and the Future of Personalized Health Care - November 16th, 2024
- Why precision medicine results in more effective health care, treatment plans - The Business Journals - November 16th, 2024
- Comprehensive Genomic Profiling at Diagnosis Extends Survival in Patients with Advanced Cancer - Inside Precision Medicine - November 16th, 2024
- More Precise Classifications of NonClear Cell RCC Are Required to Improve Personalized Treatment - OncLive - September 13th, 2024
- Bahrain aims to provide residents with personalized healthcare - Healthcare IT News - September 13th, 2024
- Precision Medicine Market Is Expected To Reach Revenue Of - GlobeNewswire - September 13th, 2024
- New Graduates Leverage Genomics Education in Clinical and Research Settings - University of Colorado Anschutz Medical Campus - June 20th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022
- AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions... - June 8th, 2022
- Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022 - Endocrinology Network - June 8th, 2022
- PreludeDx Presents New DCISionRT Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting - 69News WFMZ-TV - June 8th, 2022
- BITS Pilani Hyderabad to conduct 'Precision Medicine 2022' event tomorrow - United News of India - June 8th, 2022
- Global Laboratory Information Systems (LIS) Market to Reach US$2.4 Billion by the Year 2026 - Yahoo Finance - June 8th, 2022
- Medical Nutrition Market Promising Growth Opportunities and Forecast 2027 - Digital Journal - June 8th, 2022
- 57% of Organizations in India are at the Startup Stage of Genomics High-Performance Computing Infrastructure - APN News - June 8th, 2022
- Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies - StreetInsider.com - June 8th, 2022
- Inspiration for the laboratory of tomorrow - Chemie.de - June 8th, 2022
- Global Nanomaterials in Personalized Medicine Market (Impact Of COVID-19) Growth, Overview With Detailed Analysis 2022-2028 Queen Anne and Mangolia... - May 8th, 2022
- The global biomarkers market is expected to grow at a CAGR of 11.44%. - Yahoo Finance - May 8th, 2022
- Bioinformatics Market Size, Share, And Trends Analysis Report, By Application (Drug Development, Protein Function Analysis, Gene Therapy, Molecular... - May 8th, 2022
- Link between EBV and MS may give clues to the cause of long COVID - The Arizona Republic - May 8th, 2022
- Improving Cell Cultures with Thermoresponsive Coatings - Genetic Engineering & Biotechnology News - May 8th, 2022
- Reevaluating, Reimagining, And Reinventing Healthcare: Innovation In A Post-Pandemic World - Forbes - May 8th, 2022
- Study of Cancer Genetics to Help with Targeted Treatment - VOA Learning English - May 8th, 2022
- Increased demand for Molecular diagnostics after the COVID-19 outbreak - The Financial Express - May 8th, 2022
- CIOs' 5-year plans for precision medicine and emerging technologies - Healthcare IT News - January 30th, 2022
- SeqOne Genomics Closes 20M Series a to Accelerate the Deployment of Its Genomic Medicine Platform - Business Wire - January 30th, 2022
- Study: In IBS patients, cognitive behavioral therapy modulates the brain-gut microbiome and helps relieve symptoms - UB News Center - January 30th, 2022
- (New Report) Digital Genome Market In 2022 : The Increasing use in Diagnostics, Agriculture & Animal Research, Personalized Medicine, Drug... - January 30th, 2022
- Silencing a faulty gene may uncover clues to rare forms of ALS - National Institutes of Health - January 30th, 2022
- Plants, Bioprinting and Orbital Plumbing Fill Crew's Thursday Schedule - NASA - January 30th, 2022
- ClarityX DNA: The Key to Tackling Seasonal Affective Disorder - PR Web - January 30th, 2022